Skip to main content
. 2016 May 25;35(4):163–171. doi: 10.12938/bmfh.2016-002

Table 3. Changes in abdominal fat areas by computed tomography scan in the GCL2505-supplemented (N=69) and placebo (N=68) groups during the treatment period.

Treatment period
Time × group a
0 week
8 weeks
12 weeks
Mean 95% CI Mean 95% CI Mean 95% CI
VFA (cm2) Actual values GCL2505 133.4 126.4, 140.4 127.3 120.0, 134.6 128.3 121.2, 135.5 0.004
Placebo 124.3 118.0, 130.6 125.2 118.5, 132.0 125.8 119.3, 132.3
Change from 0 week GCL2505 - −6.8## −10.6, −2.9 −5.1# −8.6, −1.5
Placebo - 0.9 −2.6, 4.4 1.5 −1.3, 4.3
SFA (cm2) Actual values GCL2505 215.9 202.7, 229.0 213.7 200.9, 226.6 214.8 201.7, 227.8 0.676
Placebo 219.9 209.5, 230.2 216.0 204.9, 227.1 219.8 208.6, 231.0
Change from 0 week GCL2505 - −2.4 −5.9, 1.2 −1.1 −5.2, 3.0
Placebo - −3.9 −7.6, −0.1 −0.1 −3.8, 3.6
TFA (cm2) Actual values GCL2505 349.3 335.0, 363.5 341.0 326.6, 355.5 343.1 328.8, 357.4 0.111
Placebo 344.2 333.3, 355.1 341.2 329.2, 353.3 345.6 333.4, 357.7
Change from 0 week GCL2505 - −9.1 −14.2, −4.0 −6.2 −11.9, −0.5
Placebo - −3.0 −8.4, 2.5 1.4 −3.6, 6.4

Values are means and 95% confidence intervals (CIs). VFA: visceral fat area; SFA: subcutaneous fat area; TFA: total fat area.

There was a significant difference between the groups, as determined using an unpaired t-test with Bonferroni correction. #p<0.05; ##p<0.01.

ap-value represented as a group-by-time interaction effect by two-factor repeated-measures ANOVA using actual values.